These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34261320)

  • 1. A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region.
    Wang C; Wang X; Wang H; Pu J; Li Q; Li J; Liu Y; Lu L; Jiang S
    J Med Chem; 2021 Aug; 64(15):11460-11471. PubMed ID: 34261320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
    Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
    J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
    Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
    J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid Virtual Screening Approach to Predict Novel Natural Compounds against HIV-1 CCR5.
    Eid AM; Selim A; Khaled M; Elfiky AA
    J Phys Chem B; 2024 Jul; 128(29):7086-7101. PubMed ID: 39016126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
    Platt EJ; Gomes MM; Kabat D
    J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
    Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
    J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H; Otaka A; Fujii N
    Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
    Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane.
    Wang C; Li Q; Sun L; Wang X; Wang H; Zhang W; Li J; Liu Y; Lu L; Jiang S
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
    AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of coreceptor utilization to escape CCR5 antagonist therapy.
    Zhang J; Gao X; Martin J; Rosa B; Chen Z; Mitreva M; Henrich T; Kuritzkes D; Ratner L
    Virology; 2016 Jul; 494():198-214. PubMed ID: 27128349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
    Nakata H; Maeda K; Das D; Chang SB; Matsuda K; Rao KV; Harada S; Yoshimura K; Ghosh AK; Mitsuya H
    Sci Rep; 2019 Mar; 9(1):4828. PubMed ID: 30886166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.